CAJ | 학술논문

目的评价莫西沙星联合阿奇霉素治疗支原体肺炎的临床有效性及安全性.方法将80例支原体肺炎患者随机分为对照组和治疗组,两组均口服阿奇霉素治疗,治疗组在上述基础上同时口服莫西沙星,观察两组的临床指标、疗效及不良反应等情况的变化.结果经治疗后,治疗组临床症状、体征的改善时间显著优于对照组(P＜0.01).治疗组总有效率为92.5％,痰培养细菌转阴率为90.0％；对照组总有效率为75.0％,痰培养细菌转阴率为70.0％,两组之间差异有统计学意义(P＜0.05).同时,治疗组的不良反应发生率为10.0％,对照组不良反应发生率为7.5％,两组之间差异无统计学意义(P＞0.05).结论莫西沙星与阿奇霉素联合应用较单一使用阿奇霉素有更好的临床疗效,且未增加不良反应发生率,可在临床进一步推广.
목적 평개막서사성연합아기매소치료지원체폐염적림상유효성급안전성.방법 장80례지원체폐염환자수궤분위대조조화치료조,량조균구복아기매소치료,치료조재상술기출상동시구복막서사성,관찰량조적림상지표、료효급불량반응등정황적변화.결과 경치료후,치료조림상증상、체정적개선시간현저우우대조조(P＜0.01).치료조총유효솔위92.5％,담배양세균전음솔위90.0％；대조조총유효솔위75.0％,담배양세균전음솔위70.0％,량조지간차이유통계학의의(P＜0.05).동시,치료조적불량반응발생솔위10.0％,대조조불량반응발생솔위7.5％,량조지간차이무통계학의의(P＞0.05).결론 막서사성여아기매소연합응용교단일사용아기매소유경호적림상료효,차미증가불량반응발생솔,가재림상진일보추엄.
Objective To evaluate the clinical efficacy and safety of the treatment of moxifloxacin combined with azithromycin on mycoplasma pneumonia.Methods 80 patients with mycoplasma pneumonia were randomly divided into control group and treatment group.The cases in both groups were treated with azithromycin and at the same time the treatment group was given moxifloxacin.The changes of clinical parameters,efficacy and adverse reactions were observed.Results After treatment,the time of clinical improvement in treatment group was significantly better than that in control group ( P ＜0.01).The total effective rate in treatment group was 92.5 ％ and the bacteria negative rate of sputum culture was 90.0％ in treated group.While in control group,the total effective rate was 75.0％,and the bacteria negative rate was 70.0％,the difference between two groups was statistically significant (P ＜0.05).Meanwhile,the adverse reaction rate in treatment group was 10.0％,and it was 7.5％ in control group,there was no significant difference between the two groups ( P ＞ 0.05).Conclusions Moxifloxacin combined with azithromycin treated in mycoplasma pneumonia has a better clinical efficacy compared with single-use azithromycin,which does not increase the incidence of adverse reactions and can be further promoted in clinical.